<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="567">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178722</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 24360-202</org_study_id>
    <nct_id>NCT02178722</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)</brief_title>
  <official_title>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and efficacy when combining
      MK-3475 and INCB024360 in subjects with certain cancers. This study will be conducted in 2
      phases, Phase 1 and Phase 2.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase 1: Number of subjects with dose limiting toxicities (DLTs) of INCB024360 in combination with MK-3475</measure>
    <time_frame>56 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective response rate</measure>
    <time_frame>Assessed every 9 weeks for duration of study participation which is estimated to be 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Response is measured every 9 weeks for duration of study participation which is estimated to be 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events as a Measure of Safety and Tolerability of INCB024360 in combination with MK-3475</measure>
    <time_frame>Adverse events are assessed every 3 weeks for duration of study participation which is estimated to be 18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Patients are checked for survival every 12 weeks for duration of study participation which is estimated to be 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">374</enrollment>
  <condition>Malignant Solid Tumour</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Transitional Cell Carcinoma of Genitourinary Tract</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Adenocarcinoma of the Endometrium</condition>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Phase 1: MK-3475 + INCB024360</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: MK-3475 + INCB024360 25 mg BID as starting dose, followed by dose escalations (Phase 1) until recommended phase 2 dose of INCB024360 is determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: MK-3475 + INCB024360</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(recommended phase 2 dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3475</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Phase 1: MK-3475 + INCB024360</arm_group_label>
    <arm_group_label>Phase 2: MK-3475 + INCB024360</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB024360</intervention_name>
    <description>Oral daily dosing</description>
    <arm_group_label>Phase 1: MK-3475 + INCB024360</arm_group_label>
    <arm_group_label>Phase 2: MK-3475 + INCB024360</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with histologically or cytologically NSCLC, melanoma, transitional cell
             carcinoma of the GU tract, renal cell cancer, triple negative breast cancer,
             adenocarcinoma of the endometrium or squamous cell carcinoma of the head and neck
             (Phase 1)

          -  Subjects with histologically confirmed melanoma, NSCLC, transitional cell carcinoma
             of the GU tract, TNBC, SCCHN, ovarian cancer, RCC and DLBCL (Phase 2)

          -  Life expectancy &gt; 12 weeks.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.

          -  Presence of measurable disease per Response Evaluation Criteria in Solid Tumors
             (RECIST) 1.1 or Lugano Classification for subjects with DLBCL.

          -  Laboratory and medical history parameters within protocol-defined range.

          -  For Phase 1: Subjects who have advanced or metastatic disease as noted above that
             have received at least one prior therapy or have advanced or metastatic disease for
             which no curative treatment is available may be enrolled.

          -  For Phase 2 expansion cohorts: Subjects with NSCLC, melanoma, transitional cell
             carcinoma of the GU tract, SCCHN, ovarian cancer, RCC DLBCL, and TNBC.

               -  Phase 2 expansion: NSCLC

                    -  Subjects who have received at least 1 prior platinum-based therapy.
                       Subjects who have a non-platinum-based regimen may be enrolled with medical
                       monitor approval.

                    -  Tumors with epidermal growth factor receptor mutation positive or
                       anaplastic lymphoma kinase fusion oncogene positive treated with a tyrosine
                       kinase inhibitor are permitted; however, subjects should have progressed on
                       or be intolerant to the targeted therapy.

                    -  Subjects must not have received immunotherapy with PD-1 or CTLA-4 targeted
                       therapy.

               -  Phase 2 expansion: Melanoma

                    -  Documentation of V600E-activating BRAF mutation status

                    -  Subjects must not have received immunotherapy with anti-PD-1, anti-PD-L1,
                       or anti-CTLA-4 therapy.

                    -  Ocular melanoma is excluded.

               -  Phase 2 expansion: Transitional cell carcinoma of the GU tract

                    -  Metastatic or locally advanced and not amenable to curative therapy with
                       disease progression on or after platinum-based chemotherapy or alternative
                       therapy if platinum-based therapy is not appropriate.

                    -  Prior PD-1 or CTLA-4 targeted therapies are excluded

               -  Phase 2 expansion: SCCHN

                    -  Histologically confirmed metastatic or recurrent squamous cell carcinoma
                       not amenable to local therapy with curative intent (surgery or radiation
                       with or without chemotherapy). Carcinoma of the nasopharynx, salivary
                       gland, or nonsquamous histologies are excluded.

                    -  Subjects must have received at least 1 prior systemic chemotherapy regimen
                       that must have included a platinum-based therapy.

                    -  Prior PD-1 or CTLA-4 targeted therapies are excluded.

               -  Phase 2 expansion: Ovarian cancer

                    -  Subjects with FIGO Stage Ic, Stage II, Stage III, Stage IV, recurrent, or
                       persistent (unresectable) histologically confirmed epithelial ovarian
                       cancer, primary peritoneal cancer, or fallopian tube carcinoma.

                    -  Subjects must have received a platinum-taxane-based regimen as first-line
                       therapy.

                    -  Prior PD-1 or CTLA-4 targeted therapies are excluded.

                    -  Borderline, low-malignant-potential epithelial carcinoma per histopathology
                       is excluded.

               -  Phase 2 expansion: Relapsed or refractory DLBCL

                    -  Prior allogeneic stem-cell transplantation is excluded.

                    -  Must have received &gt; or = 1 prior treatment regimen.

                    -  Not a candidate for curative therapy or hematopoietic stem-cell
                       transplantation (either due to disease burden, fitness, or preference).

                    -  Prior PD-1 or CTLA-4 targeted therapies are excluded.

               -  Phase 2 expansion: TNBC

                    -  Histologically confirmed breast adenocarcinoma that is unresectable loco
                       regional, or metastatic.

                    -  Pathologically confirmed as triple negative, source documented, defined as
                       both of the following:

                    -  Estrogen receptor (ER) and progesterone receptor (PgR) negative

                    -  Human epidermal growth factor receptor 2 (HER2) negative as per American
                       Society of Clinical Oncology/College of American Pathologists guidelines

                    -  Subject must have received at least 1 prior systemic regimen for advanced
                       or metastatic disease.

                    -  Prior PD-1 or CTLA-4 targeted therapies are excluded.

               -  Phase 2 expansion: RCC

                    -  Subjects with histological or cytological confirmation of clear cell RCC.

                    -  Not curable by surgery.

                    -  Progression during or after available therapies with established clinical
                       benefit, intolerant to therapy, or refused standard therapy.

               -  Tumor biopsies are required. If a subject has inaccessible lesions, such as in
                  ovarian cancer, or highly vascular lesions, such as RCC, enrollment may be
                  considered with medical monitor approval, and archived tissue may be acceptable.

               -  Females of child-bearing potential and males who use adequate birth control
                  through 120 days post dose.

        Exclusion Criteria:

          -  Subjects who participated in any other study in which receipt of an investigational
             study drug or device occurred within 28 days or 5 half-lives (whichever is longer)
             prior to first dose.

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation
             or checkpoint pathways).

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate
             provided they are stable.

          -  Has an active autoimmune disease.

          -  Has evidence of interstitial lung disease or pneumonitis.

          -  Live vaccine use within 30 days of first dose of study medication

          -  Monoamine oxidase inhibitors
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Jones, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Call Center</last_name>
    <phone>1-855-463-3463</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 16, 2016</lastchanged_date>
  <firstreceived_date>June 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
